SUBSCRIBE
SUBSCRIBE

Apnimed

39 John F Kennedy Street Cambridge MA 02138 US
Visit website
Email Us
  • Featured Employer
JOBS
IN THE PRESS
Drug Development
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
May 15, 2023
 · 
5 min read
Genetown
Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
 · 
3 min read
Genetown
Apnimed to Participate in the SVB Securities Global Biopharma Conference
January 25, 2023
 · 
3 min read
Drug Development
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)
January 3, 2023
 · 
4 min read
Genetown
Apnimed to Present at the Stifel Healthcare Conference
November 8, 2022
 · 
3 min read
Genetown
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
October 17, 2022
 · 
7 min read
Genetown
Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum
October 12, 2022
 · 
3 min read
Business
Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development
October 5, 2022
 · 
5 min read
Genetown
Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference
August 4, 2022
 · 
2 min read
FDA
Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)
June 28, 2022
 · 
4 min read
Load More